Segmented Poly(A) Tails Significantly Reduce Recombination of Plasmid DNA Without Affecting MRNA Translation Efficiency or Half-life

Overview

Journal RNA

Specialty Molecular Biology

Date 2019 Jan 17

PMID 30647100

Citations 40

Authors

Zeljka Trepotec

Johannes Geiger

Christian Plank

Manish K Aneja

Carsten Rudolph

Affiliations

Soon will be listed here.

Abstract

Extensive research in the past decade has brought mRNA closer to the clinical realization of its therapeutic potential. One common structural feature for all cellular messenger RNAs is a poly(A) tail, which can either be brought in cotranscriptionally via the DNA template (plasmid- or PCR-based) or added to the mRNA in a post-transcriptional enzymatic process. Plasmids containing poly(A) regions recombine in , resulting in extensive shortening of the poly(A) tail. Using a segmented poly(A) approach, we could significantly reduce recombination of plasmids in without any negative effect on mRNA half-life and protein expression. This effect was independent of the coding sequence. A segmented poly(A) tail is characterized in that it consists of at least two A-containing elements, each defined as a nucleotide sequence consisting of 40-60 adenosines, separated by a spacer element of different length. Furthermore, reducing the spacer length between the poly(A) segments resulted in higher translation efficiencies compared to homogeneous poly(A) tail and reduced recombination (depending upon the choice of spacer nucleotide). Our results demonstrate the superior potential of segmented poly(A) tails compared to the conventionally used homogeneous poly(A) tails with respect to recombination of the plasmids and the resulting mRNA performance (half-life and translational efficiency).

Citing Articles

mRNA Galsomes Vaccine Protects Budgerigars Against Virulent Challenge.

De Meyst A, Van Mieghem J, Chiers K, Raemdonck K, Verbeke R, Lentacker I Vaccines (Basel). 2025; 13(2).

PMID: 40006752 PMC: 11861616. DOI: 10.3390/vaccines13020206.

A capless hairpin-protected mRNA vaccine encoding the full-length Influenza A hemagglutinin protects mice against a lethal Influenza A infection.

Solodushko V, Kim J, Fouty B Gene Ther. 2025; .

PMID: 39988620 DOI: 10.1038/s41434-025-00521-0.

Design and Expression of Multiepitope Constructs Using mRNA Vaccine Technology.

Sanchez-Montejo J, Strilets T, Manzano-Roman R, Lopez-Aban J, Garcia-Blanco M, Vicente B Int J Mol Sci. 2025; 26(3).

PMID: 39940957 PMC: 11818309. DOI: 10.3390/ijms26031190.

A generative framework for enhanced cell-type specificity in rationally designed mRNAs.

Khoroshkin M, Zinkevich A, Aristova E, Yousefi H, Lee S, Mittmann T bioRxiv. 2025; .

PMID: 39803435 PMC: 11722239. DOI: 10.1101/2024.12.31.630783.

Altering the intracellular trafficking of Necator americanus GST-1 antigen yields novel hookworm mRNA vaccine candidates.

De Oliveira A, Versteeg L, Briggs N, Adhikari R, Villar M, Redd J PLoS Negl Trop Dis. 2025; 19(1):e0012809.

PMID: 39792959 PMC: 11756802. DOI: 10.1371/journal.pntd.0012809.

References

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

Bangel-Ruland N, Tomczak K, Fernandez Fernandez E, Leier G, Leciejewski B, Rudolph C . Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy. J Gene Med. 2013; 15(11-12):414-26. DOI: 10.1002/jgm.2748. View

Williams A, Marzluff W . The sequence of the stem and flanking sequences at the 3' end of histone mRNA are critical determinants for the binding of the stem-loop binding protein. Nucleic Acids Res. 1995; 23(4):654-62. PMC: 306734. DOI: 10.1093/nar/23.4.654. View

Voet J, Voet D . We have a new publisher: John Wiley & Sons. Biochem Mol Biol Educ. 2011; 35(1):1. DOI: 10.1002/bmb.20. View

Goldstrohm A, Wickens M . Multifunctional deadenylase complexes diversify mRNA control. Nat Rev Mol Cell Biol. 2008; 9(4):337-44. DOI: 10.1038/nrm2370. View

Richner J, Himansu S, Dowd K, Butler S, Salazar V, Fox J . Modified mRNA Vaccines Protect against Zika Virus Infection. Cell. 2017; 169(1):176. DOI: 10.1016/j.cell.2017.03.016. View

Mangus D, Evans M, Jacobson A . Poly(A)-binding proteins: multifunctional scaffolds for the post-transcriptional control of gene expression. Genome Biol. 2003; 4(7):223. PMC: 193625. DOI: 10.1186/gb-2003-4-7-223. View

Trepotec Z, Aneja M, Geiger J, Hasenpusch G, Plank C, Rudolph C . Maximizing the Translational Yield of mRNA Therapeutics by Minimizing 5'-UTRs. Tissue Eng Part A. 2018; 25(1-2):69-79. DOI: 10.1089/ten.TEA.2017.0485. View

Grier A, Burleigh S, Sahni J, Clough C, Cardot V, Choe D . pEVL: A Linear Plasmid for Generating mRNA IVT Templates With Extended Encoded Poly(A) Sequences. Mol Ther Nucleic Acids. 2016; 5:e306. PMC: 5014522. DOI: 10.1038/mtna.2016.21. View

10.

Lodish H . Translational control of protein synthesis: the early years. J Biol Chem. 2012; 287(43):36528-35. PMC: 3476319. DOI: 10.1074/jbc.X112.420356. View

11.

Kapeli K, Yeo G . Genome-wide approaches to dissect the roles of RNA binding proteins in translational control: implications for neurological diseases. Front Neurosci. 2012; 6:144. PMC: 3462321. DOI: 10.3389/fnins.2012.00144. View

12.

Ferizi M, Aneja M, Balmayor E, Badieyan Z, Mykhaylyk O, Rudolph C . Human cellular CYBA UTR sequences increase mRNA translation without affecting the half-life of recombinant RNA transcripts. Sci Rep. 2016; 6:39149. PMC: 5156912. DOI: 10.1038/srep39149. View

13.

Cao G, Sarkar N . Identification of the gene for an Escherichia coli poly(A) polymerase. Proc Natl Acad Sci U S A. 1992; 89(21):10380-4. PMC: 50342. DOI: 10.1073/pnas.89.21.10380. View

14.

Bernal J . RNA-based tools for nuclear reprogramming and lineage-conversion: towards clinical applications. J Cardiovasc Transl Res. 2013; 6(6):956-68. PMC: 3838600. DOI: 10.1007/s12265-013-9494-8. View

15.

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

16.

Mullard A . mRNA-based drug approaches Phase I milestone. Nat Rev Drug Discov. 2016; 15(9):595. DOI: 10.1038/nrd.2016.182. View

17.

Baer B, Kornberg R . The protein responsible for the repeating structure of cytoplasmic poly(A)-ribonucleoprotein. J Cell Biol. 1983; 96(3):717-21. PMC: 2112416. DOI: 10.1083/jcb.96.3.717. View

18.

Godiska R, Mead D, Dhodda V, Wu C, Hochstein R, Karsi A . Linear plasmid vector for cloning of repetitive or unstable sequences in Escherichia coli. Nucleic Acids Res. 2009; 38(6):e88. PMC: 2847241. DOI: 10.1093/nar/gkp1181. View

19.

Preiss T, Muckenthaler M, Hentze M . Poly(A)-tail-promoted translation in yeast: implications for translational control. RNA. 1998; 4(11):1321-31. PMC: 1369706. DOI: 10.1017/s1355838298980669. View

20.

Kormann M, Hasenpusch G, Aneja M, Nica G, Flemmer A, Herber-Jonat S . Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol. 2011; 29(2):154-7. DOI: 10.1038/nbt.1733. View